Evidence map›Paper›PMID 39841788›Full record

ArticlePLoS pathogens2025

A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies.

Melanie Rissmann, Danny Noack, Thomas M Spliethof, Vincent P Vaes, Rianne Stam, Peter van Run, Jordan J Clark, Georges M G M Verjans, Bart L Haagmans, Florian Krammer and 3 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Melanie RissmannDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-5298-5919
Danny NoackDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-1845-7511
Thomas M SpliethofDivision of Pathology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
Vincent P VaesDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Rianne StamDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Peter van RunDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Jordan J ClarkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.ORCID 0000-0003-1790-7883
Georges M G M VerjansDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-2465-2674
Bart L HaagmansDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-6221-2015
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.ORCID 0000-0003-4121-776X
Marion P G KoopmansDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-5204-2312
Judith M A van den BrandDivision of Pathology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0001-8420-5406
Barry RockxDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-2463-027X

Funding

Health~HollandNetherlands Centre for One Health Ph.D. Research Program
6 · The paper itself

Abstract

Orthohantaviruses are emerging zoonotic viruses that can infect humans via the respiratory tract. There is an unmet need for an in vivo model to study infection of different orthohantaviruses in physiologically relevant tissue and to assess the efficacy of novel pan-orthohantavirus countermeasures. Here, we describe the use of a human lung xenograft mouse model to study the permissiveness for different orthohantavirus species and to assess its utility for preclinical testing of therapeutics. Following infection of xenografted human lung tissues, distinct orthohantavirus species differentially replicated in the human lung and subsequently spread systemically. The different orthohantaviruses primarily targeted the endothelium, respiratory epithelium and macrophages in the human lung. A proof-of-concept preclinical study showed treatment of these mice with a virus neutralizing antibody could block Andes orthohantavirus infection and dissemination. This pan-orthohantavirus model will facilitate progress in the fundamental understanding of pathogenesis and virus-host interactions for orthohantaviruses. Furthermore, it is an invaluable tool for preclinical evaluation of novel candidate pan-orthohantavirus intervention strategies.

Indexed as

Disease Models, AnimalHantavirus InfectionsLungOrthohantavirusAnimalsAntibodies, NeutralizingHeterograftsHumansMiceAntibodies, Neutralizing

Identifiers

PMID39841788
PMCPMC11774489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.